NJ Bio and Ajinomoto Bio-Pharma Services Partner to Advance Antibody-Drug Conjugate Development Through AJICAP™ Platform Integration
核心洞察
NJ Bio (搜索), Inc. and Ajinomoto Bio-Pharma Services (搜索) announced a research collaboration to integrate the AJICAP™ (搜索) site-specific conjugation platform into NJ Bio's discovery and development workflows for antibody-drug conjugates (搜索).
The AJICAP™ (搜索) platform enables precise chemical modification at defined lysine residues (搜索) without antibody engineering, preserving structure and functionality while improving pharmacokinetics and therapeutic index.
This partnership strengthens NJ Bio (搜索)'s position as a comprehensive partner for biopharmaceutical companies, offering end-to-end support from early drug design through preclinical development.
NJ Bio (搜索), Inc., a leading contract research and development organization, has entered into a strategic research collaboration with Ajinomoto Bio-Pharma Services (搜索) to expand access to the AJICAP™ (搜索) site-specific conjugation platform for antibody-drug conjugate (ADC) development. The partnership, announced in March 2026, aims to strengthen support for next-generation targeted therapeutics through enhanced conjugation capabilities.
AJICAP™ Platform Integration Enhances ADC Development Capabilities
Through this collaboration, NJ Bio (搜索) will integrate the AJICAP™ (搜索) platform into its discovery and development workflows, offering clients a robust and highly reproducible approach for site-specific conjugation of both cytotoxic and non-cytotoxic payloads to antibodies. The AJICAP™ technology enables precise chemical modification at defined lysine residues (搜索) without requiring antibody engineering, preserving antibody structure and functionality while improving pharmacokinetics, therapeutic index, and overall developability.
The platform supports a range of stable, hydrophilic linker systems and can be readily incorporated into drug discovery and development programs. AJICAP™ (搜索) technology is recognized for its scalability, consistency, and compatibility with standard antibody production processes, making it an attractive option for biopharmaceutical companies seeking reliable conjugation solutions.
Strategic Benefits for Biopharmaceutical Development
By integrating the AJICAP™ (搜索) platform, NJ Bio (搜索) strengthens its position as a comprehensive partner for biopharmaceutical companies seeking end-to-end support, from early drug design and discovery through preclinical development. Clients will benefit from NJ Bio's expertise in medicinal chemistry, bioconjugation, and biologics development, combined with the precision, reproducibility, and flexibility of the AJICAP™ platform.
Based on prior technical experience working with AJICAP™ (搜索) technology, NJ Bio (搜索) anticipates that this collaboration will help reduce development risk, shorten timelines, and improve overall project outcomes for ADC programs.
Industry Leadership Perspectives
"Expanding our capabilities with AJICAP™ (搜索) aligns strongly with NJ Bio (搜索)'s mission to deliver cutting-edge, high-value solutions that accelerate our clients' discovery programs," said Julien Dugal-Tessier, President and Chief Scientific Officer at NJ Bio. "This collaboration enables us to offer a proven, scalable site-specific conjugation platform, expand access to AJICAP™ capabilities, and support the development of novel antibody-based medicines with improved efficacy and safety profiles."
Yasuyuki Otake, Corporate Executive and General Manager of the Bio-Pharma Services Department at Ajinomoto Co., Inc., emphasized the collaborative potential: "AJICAP™ (搜索) was developed to enable precise and scalable antibody conjugation, and we are excited to extend its reach through this collaboration with NJ Bio (搜索). Together, we are enhancing the tools available to biopharma innovators to design and develop next-generation targeted therapies for patients."
Company Profiles and Expertise
NJ Bio (搜索) operates as a leading Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) headquartered in Princeton, New Jersey, with additional chemistry facilities in Bristol, Pennsylvania and Mumbai, India. The company provides fully integrated chemistry and biology services to biotechnology and pharmaceutical companies, supporting programs from early discovery through GMP manufacturing. NJ Bio specializes in ADCs (搜索), targeted protein degraders (搜索) (TPDs (搜索)), oligo-conjugates (搜索), and other non-oncology conjugated therapeutics, and has been recognized as "Best Contract Research Organization (CRO)" for multiple consecutive years at the World ADC Conference.
Ajinomoto Bio-Pharma Services (搜索) operates as a fully integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and the United States. The company provides support across gene therapy, APIs, and both large- and small-molecule manufacturing, offering innovative platforms including high-potency APIs (HPAPI), continuous-flow manufacturing, oligonucleotide synthesis, biocatalysis, CORYNEX® protein expression technology, and antibody-drug conjugation services.